Imaging Endpoints, the global leader in oncology-trial imaging and one of the largest imaging service providers in the world, is pleased to announce the to announce the appointment of Manish Sharma, MD as Scientific Director.
dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging and data science, comes to Imaging Endpoints with a proven track record of excellence. In addition to supporting regulatory approvals for several breakthrough therapies, including priority review and accelerated approvals, his pioneering work in image analytics and the use of big data to improve reader performance and reduce variability leads the industry. He has also made significant advances in the application of AI/ML techniques, including deep learning applications in radiological imaging.
“Manish’s extensive expertise and innovative approach align perfectly with our vision (to connect imaging to healing),” said Ronald Korn , MD, PhD, Chief Physician and Founder of Imaging Endpoints. “His leadership in medical and regulatory strategy, including IND, NDA, ANDA and 505(b)(2) submissions, will further enhance the depth and expertise of our Independent Central Review Services.”
Also Read : Neogen® Wins Best Innovative Luminol-Based Substrate Award
dr medical Sharma will lead medical and scientific affairs as well as research and development at Imaging Endpoints. His proven leadership, ability to develop and launch new services, and globally recognized expertise in clinical trial imaging will be instrumental in accelerating the leadership, growth and success of Imaging Endpoints.
“Ron Korn is recognized in the industry as a leading expert in oncology clinical trial imaging. With the addition of Manish Sharma , we expect to be able to support more oncology trials and approvals than any other iCRO over the next few years thanks to the pair’s combined exceptional talents,” said Doug Dean Burkett , PhD, CEO and Chairman. “Dr. Sharmas Deep clinical trial imaging expertise, outstanding data quality assurance expertise, and ability to drive advances in data analytics will help us continue to set new standards as the preferred iCRO partner for biopharma companies around the world .”
“Joining Imaging Endpoints is an exciting opportunity to join a leading team that shares my passion for connecting imaging with therapeutic solutions,” said Dr. Sharma. “As clinical trial designs become increasingly complex, innovation plays a role the industry plays a critical role in leveraging all available scientific information from images and metadata for the benefit of sponsors and patients. I look forward to using my experience to drive innovation and excellence in. through new methodologies and my commitment to pushing boundaries advance imaging for clinical trials and improve our support for the most impactful clinical trials in oncology worldwide.”
SOURCE : PRNewswire